-
Product Insights
Osteonecrosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Osteonecrosis - Drugs In Development, 2023’, provides an overview of the Osteonecrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Osteonecrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Osteoporosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Osteoporosis - Drugs In Development, 2023’, provides an overview of the Osteoporosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Osteoporosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Axial Spondyloarthritis – Drugs In Development, 2023
Global Markets Direct’s, ‘Axial Spondyloarthritis - Drugs In Development, 2023’, provides an overview of the Axial Spondyloarthritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Axial Spondyloarthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Ankylosing Spondylitis (Bekhterev’s Disease) – Drugs In Development, 2023
Global Markets Direct’s, ‘Ankylosing Spondylitis (Bekhterev's Disease) - Drugs In Development, 2023’, provides an overview of the Ankylosing Spondylitis (Bekhterev's Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ankylosing Spondylitis (Bekhterev's Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Telisotuzumab Vedotin in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Telisotuzumab Vedotin in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Telisotuzumab Vedotin in Non-Small Cell Lung Cancer Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RAB-001 in Osteoporosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RAB-001 in Osteoporosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.RAB-001 in OsteoporosisDrug Details:RAB-001 is under development for the treatment of osteoporosis, osteonecrosis, fracture...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RAB-001 in Osteonecrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RAB-001 in Osteonecrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.RAB-001 in OsteonecrosisDrug Details:RAB-001 is under development for the treatment of osteoporosis, osteonecrosis, fracture...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Maplirpacept in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Maplirpacept in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Maplirpacept in Relapsed Multiple MyelomaDrug Details:Maplirpacept (TTI-622) is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – RAB-001
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry RAB-001 Drug Details RAB-001 is under development for the treatment of osteoporosis, osteonecrosis, fracture...
-
Product Insights
Osteonecrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Osteonecrosis is bone death caused by the poor blood supply to the area. It is most common in the hip and shoulder but can affect other large joints such as the knee, elbow, wrist, and ankle. Osteonecrosis can be caused by disease, or severe trauma, such as a break or dislocation, that affects the blood supply to the bone. There are no symptoms in the early stages. The Osteonecrosis  pipeline drugs market report provides comprehensive information on the therapeutics under...